Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.55 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.55 |
| ▸ | CX3CR1 | P49238 | 1/20 | 0.54 |
| ▸ | OPRK1 | P41145 | 9/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.45 |
| ▸ | HTR7 | P34969 | 3/20 | 0.45 |
| ▸ | HTR1A | P08908 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20551988 | 0.88 | ADRB2 (0.56) | ADRB2ADRA2ACX3CR1OPRK1DRD3 | |
| SCHEMBL20551994 | 0.86 | OPRK1 (0.53) | ADRB2ADRA2AOPRK1OPRM1HTR7 | |
| SCHEMBL20553531 | 0.83 | OPRK1 (0.58) | ADRB2ADRA2ACX3CR1OPRK1DRD3 | |
| SCHEMBL21751222 | 0.81 | OPRM1 (0.54) | ADRB2ADRA2ACX3CR1OPRK1DRD3 | |
| SCHEMBL20553530 | 0.79 | ADRB2 (0.56) | ADRB2ADRA2ACX3CR1OPRK1HTR7 | |
| SCHEMBL20551971 | 0.78 | ADRB2 (0.53) | ADRB2ADRA2ACX3CR1OPRK1OPRM1 | |
| SCHEMBL21751214 | 0.78 | ADRB2 (0.58) | ADRB2ADRA2ACX3CR1OPRK1OPRM1 | |
| SCHEMBL29424028 | 0.78 | ADRB2 (0.58) | ADRB2ADRA2ACX3CR1OPRK1OPRM1 | |
| SCHEMBL20553400 | 0.77 | OPRK1 (0.59) | ADRB2ADRA2ACX3CR1OPRK1OPRM1 | |
| SCHEMBL20553700 | 0.77 | ADRB2 (0.55) | ADRB2ADRA2ACX3CR1OPRK1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200062768-A1 | CX3CR1 Small Molecule Antagonists, and Methods Using Same | DREXEL UNIVERSITY | 2020-02-27 | — | — | US | claimed |
| US-12630555-B2 | Substituted pyrrolo[1,2-a]quinoxalin-4(5H)-ones as CX3CR1 antagonists | DREXEL UNIVERSITY (US) | 2026-05-19 | — | — | US | disclosed |
| US-20240409544-A1 | SUBSTITUTED PYRROLO[1,2-a]QUINOXALIN-4(5H)-ONES AS CX3CR1 ANTAGONISTS | DREXEL UNIVERSITY | 2024-12-12 | — | — | US | disclosed |
| US-12152036-B2 | Substituted pyrrolo[1,2-α]quinoxalin-4(5H)-ones as CX3CR1 antagonists | DREXEL UNIVERSITY (US) | 2024-11-26 | — | — | US | disclosed |
| US-20220144845-A1 | SUBSTITUTED PYRROLO[1,2-a]QUINOXALIN-4(5H)-ONES AS CX3CR1 ANTAGONISTS | UNIV DREXEL (US) | 2022-05-12 | — | — | US | disclosed |
| US-20220144845-A1 | SUBSTITUTED PYRROLO[1,2-a]QUINOXALIN-4(5H)-ONES AS CX3CR1 ANTAGONISTS | UNIV DREXEL (US) | 2022-05-12 | — | — | US | disclosed |
| US-11267817-B2 | Substituted pyrrolo[1,2-a]quinoxalin-4(5H)-ones as CX3CR1 antagonists | DREXEL UNIVERSITY (US) | 2022-03-08 | — | — | US | disclosed |
| US-20200062768-A1 | CX3CR1 Small Molecule Antagonists, and Methods Using Same | DREXEL UNIVERSITY | 2020-02-27 | — | — | US | disclosed |
| US-20200062768-A1 | CX3CR1 Small Molecule Antagonists, and Methods Using Same | DREXEL UNIVERSITY | 2020-02-27 | — | — | US | disclosed |
| WO-2018204370-A1 | CX3CR1 SMALL MOLECULE ANTAGONISTS, AND METHODS USING SAME | DREXEL UNIVERSITY (US) | 2018-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240409544-A1 | SUBSTITUTED PYRROLO[1,2-a]QUINOXALIN-4(5H)-ONES AS CX3CR1 ANTAGONISTS | CX3CR1, CCR5, CCL2 | ADRB2 517/4885ADRA2A 527/4885CX3CR1 1/4885 |
| US-20220144845-A1 | SUBSTITUTED PYRROLO[1,2-a]QUINOXALIN-4(5H)-ONES AS CX3CR1 ANTAGONISTS | CX3CR1, CCR5, CCL2 | ADRB2 517/4885ADRA2A 527/4885CX3CR1 1/4885 |
| US-20200062768-A1 | CX3CR1 Small Molecule Antagonists, and Methods Using Same | CX3CR1, CCR5, CXCR3 | ADRB2 621/4885ADRA2A 689/4885CX3CR1 1/4885 |
| US-11267817-B2 | Substituted pyrrolo[1,2-a]quinoxalin-4(5H)-ones as CX3CR1 antagonists | CX3CR1, CCR5, CCL2 | ADRB2 597/4885ADRA2A 591/4885CX3CR1 1/4885 |
| US-12630555-B2 | Substituted pyrrolo[1,2-a]quinoxalin-4(5H)-ones as CX3CR1 antagonists | CX3CR1, CCL2, CCR2 | ADRB2 250/4885ADRA2A 629/4885CX3CR1 1/4885 |
| US-12152036-B2 | Substituted pyrrolo[1,2-α]quinoxalin-4(5H)-ones as CX3CR1 antagonists | CX3CR1, CCR5, CCL2 | ADRB2 437/4885ADRA2A 493/4885CX3CR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.